Pfizer, Genmab’s ADC Tivdak Scores Full FDA Approval in Recurrent or Metastatic Cervical Cancer

The FDA has granted full approval to Pfizer and Genmab’s antibody-drug conjugate Tivdak for the treatment of recurrent or metastatic cervical cancer that had progressed on or after chemotherapy.

Chris Boshoff, chief oncology officer at Pfizer, said in a statement that Monday’s regulatory victory “reinforces the important role of Tivdak” for the treatment of patients with this condition, which he calls “a particularly devastating and mostly incurable disease.”

Tivdak is an antibody-drug conjugate (ADC) originally developed under a partnership between Seagen and Genmab. Pfizer took over Seagen’s half of the deal when it bought the cancer-focused biotech in March 2023 for $43 billion.

READ THE STORY at BioSpace »

Photo credit: iStock